C-Ray Therapeutics
Investors
Venture capital firms, private equity investors, and strategic partners
Common Investor Types
- •Venture Capital Firms: Early-stage and growth equity investors
- •Private Equity: Later-stage institutional investors
- •Strategic Investors: Corporations in related industries
- •Angel Investors: High-net-worth individuals
- •Family Offices: Private wealth management firms
What Investors Provide
- ✓Capital for growth and expansion
- ✓Strategic guidance and expertise
- ✓Industry connections and partnerships
- ✓Market validation and credibility
- ✓Board representation and governance
Who Invested in C-Ray Therapeutics?
C-Ray Therapeutics has attracted investment from 10+ venture capital firms, private equity investors, and strategic partners across 0 funding rounds. These investors have provided a total of $102M in capital to fuel the company's growth.
Why Do Investors Fund C-Ray Therapeutics?
Investors are attracted to C-Ray Therapeutics due to the company's strong market position, growth potential, and proven business model.
Types of C-Ray Therapeutics Investors
C-Ray Therapeutics investors typically include a mix of venture capital firms providing growth capital, private equity firms for later-stage funding, strategic corporate investors from related industries, and high-net-worth angel investors. Each investor type brings unique value beyond capital, including industry expertise, strategic partnerships, and operational guidance.
Investor FAQs
How many investors does C-Ray Therapeutics have?
C-Ray Therapeutics has had 10+ investors participate across its funding rounds. This includes venture capital firms, private equity investors, strategic partners, and angel investors.
Who are the lead investors in C-Ray Therapeutics?
Lead investors typically invest the largest amounts and often take board seats. For detailed information about C-Ray Therapeutics's lead investors and cap table structure, please contact our team.
Can I become an investor in C-Ray Therapeutics?
Accredited investors can purchase C-Ray Therapeutics shares on the secondary market through Premier Alternatives. This provides an opportunity to invest in the company before a potential IPO or acquisition event.